SCHEMBL19101786

SCHEMBL19101786

Nc1nc(F)nn2c(C3O[C@H](COCc4ccccc4)[C@@H](OCc4ccccc4)[C@H]3F)ccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE2A O00408 2/20 0.48
▸ HTR1A P08908 1/20 0.39
▸ PTPN1 P18031 8/20 0.38
▸ CDC25B P30305 8/20 0.38
▸ PTPN2 P17706 4/20 0.38
▸ PTPN6 P29350 4/20 0.38
▸ PTPN11 Q06124 4/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ CA9 Q16790 1/20 0.38
▸ GJB2 P29033 2/20 0.35
▸ TP53 P04637 1/20 0.35
▸ MDM2 Q00987 1/20 0.35
▸ HSPA5 P11021 1/20 0.35
▸ BCHE P06276 1/20 0.34
▸ SSTR1 P30872 1/20 0.34
▸ SSTR2 P30874 1/20 0.34
▸ SSTR4 P31391 1/20 0.34
▸ SSTR3 P32745 1/20 0.34
▸ SSTR5 P35346 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16701323 1.00 PDE2A (0.48) PDE2AHTR1APTPN1CDC25BPTPN2
SCHEMBL18787314 0.86 PDE2A (0.51) PDE2AHTR1APTPN1CDC25BPTPN2
SCHEMBL19227796 0.84 PDE2A (0.49) PDE2AHTR1APTPN1CDC25BPTPN2
SCHEMBL18636426 0.84 PDE2A (0.49) PDE2AHTR1APTPN1CDC25BPTPN2
SCHEMBL30873316 0.80 PDE2A (0.48) PDE2AHTR1APTPN1CDC25BPTPN2
SCHEMBL18787315 0.78 PDE2A (0.52) PDE2AHTR1APTPN1CDC25BPTPN2
SCHEMBL20404030 0.78 PDE2A (0.42) PDE2AHTR1AHSPA5
SCHEMBL16698934 0.77 PDE2A (0.39) PDE2AHTR1APTPN1CDC25BPTPN2
SCHEMBL24557986 0.76 PDE2A (0.59) PDE2AHTR1APTPN1CDC25BCA1
SCHEMBL17106818 0.75 HTR1A (0.43) PDE2AHTR1APTPN1CDC25BPTPN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10377761-B2 Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections GILEAD SCIENCES, INC. (US) 2019-08-13 — — US disclosed
US-20190055253-A1 PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS GILEAD SCIENCES, INC. 2019-02-21 — — US disclosed
US-20180016280-A1 PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS GILEAD SCIENCES, INC. 2018-01-18 — — US disclosed
US-20170226140-A1 2' FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. 2017-08-10 — — US disclosed
US-9701682-B2 Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections GILEAD SCIENCES, INC. (US) 2017-07-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170226140-A1 2' FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT PNP, NUDT1, NSUN2 PDE2A 1006/4885HTR1A 2056/4885PTPN1 1695/4885
US-20180016280-A1 PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS SYNJ1, SARS1, SYNJ2 PDE2A 3391/4885HTR1A 544/4885PTPN1 1895/4885
US-10377761-B2 Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections SYNJ1, SARS1, SYNJ2 PDE2A 3391/4885HTR1A 544/4885PTPN1 1895/4885
US-20190055253-A1 PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS SYNJ1, SARS1, SYNJ2 PDE2A 3391/4885HTR1A 544/4885PTPN1 1895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback